Molecular profiling of soft tissue sarcomas using next-generation sequencing: A pilot study toward precision therapeutics

George Jour*, John D. Scarborough, Robin L. Jones, Elizabeth Loggers, Seth M. Pollack, Colin C. Pritchard, Benjamin L. Hoch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Next-generation sequencing (NGS) can provide in-depth detection of numerous gene alterations. To date, there are very few reports describing the use of this technique in soft tissue sarcomas. Herein, we aim to test the utility of NGS in identifying targetable mutations in these tumors. NGS was performed using a clinically validated multiplexed gene sequencing panel interrogating the full coding sequence of 194 cancer-related genes. A custom bioinformatics pipeline was developed to detect all classes of mutations directly from the NGS data, including single-nucleotide variants, small insertions and deletions, copy number variation, and complex structural variations. Twenty-five soft tissue sarcomas were analyzed; 18 of these patients had metastatic disease and 7 primary locally advanced tumors. Targetable mutations for which clinical trials are available were identified in 60% of the cases. MAP2K4, AURKA, AURKB, and c-MYC amplification were recurrent events in leiomyosarcomas. Frequent non-targetable variants included copy losses of the TP53 (24%), PTEN (16%), and CDKN2A (20%). Additional frameshift mutations, deletion mutations, and single-nucleotide variants involving numerous genes, including RB1, NOTCH1, PIK3CA, PDGFRB, EPHA5, KDM6A, NF1, and FLT4 genes, were also identified. NGS is useful in identifying targetable mutations in soft tissue sarcomas that can serve as a rationale for inclusion of patients with advanced disease in ongoing clinical trials and allow for better risk stratification.

Original languageEnglish (US)
Pages (from-to)1563-1571
Number of pages9
JournalHuman pathology
Volume45
Issue number8
DOIs
StatePublished - Aug 2014
Externally publishedYes

Keywords

  • Molecular profiling
  • Next generation sequencing
  • Precision therapeutics
  • Soft tissue sarcoma
  • Targetable mutations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Molecular profiling of soft tissue sarcomas using next-generation sequencing: A pilot study toward precision therapeutics'. Together they form a unique fingerprint.

Cite this